🇺🇸 FDA
Patent

US 11001610

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

granted A61KA61K38/00A61K47/60

Quick answer

US patent 11001610 (Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof) held by Apellis Pharmaceuticals, Inc. expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K38/00, A61K47/60, A61K47/643, A61P